The use of artificial intelligence in clinical trials holds immense promise, from accelerating drug discovery to optimizing patient recruitment and trial design. However, the integration of AI also introduces complex ethical considerations that must be carefully navigated.

Watch the recording as panellists from Novartis, ICON PLC, and Astellas Pharma explored the ethical implications of AI use in clinical trials, paying attention to emerging risks, key considerations, and future trends.

*Disclaimer: The speaker is a paid employee of Astellas. This presentation is intended for informational purposes only and does not replace independent professional judgment. This presentation is not intended to provide medical or legal advice. Statements of fact, positions taken and opinions expressed are those of the speaker individually and, unless expressly stated to the contrary, do not necessarily reflect the opinion or position of the speaker’s employer, Astellas, or any of its subsidiaries and/or related entities.*